News
Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...
Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...
Needham upgraded Gilead Sciences (NASDAQ:GILD) to Buy from Hold on Friday, citing a physical survey to suggest that the ...
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
1d
Long Island Press on MSNNorthwell now offering new prevention injection to combat HIV and AIDSNorthwell Health is now offering a new injection that promises to reduce the risk of HIV and AIDS. Doctors say it will combat ...
Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated ...
Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs down, Europe’s Committee for Medicinal Products ...
11d
GlobalData on MSNWHO endorses Gilead’s Yeztugo for HIV preventionThe WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...
Gilead on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers lenacapavir for use as pre-exposure prophylaxis, or PrEP, to reduce ...
DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results